Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1150 ARTÍCULOS , VIENDO DEL 151 AL 165

Retinoids for treatment of Alzheimer's disease

Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G.

Biofactors. 2012 Mar-Apr;38(2):84-9. doi: 10.1002/biof.196. Epub 2012 Mar 15.

Vitamin E in aging, dementia, and Alzheimer's disease

Joshi YB, Praticò D.

Biofactors. 2012 Mar-Apr;38(2):90-7. doi: 10.1002/biof.195. Epub 2012 Mar 16.

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Brunden KR.

J Neurosci. 2012 Mar 14;32(11):3601-11. doi: 10.1523/JNEUROSCI.4922-11.2012.

Alzheimer mechanisms and therapeutic strategies

Huang Y, Mucke L.

Cell. 2012 Mar 16;148(6):1204-22. doi: 10.1016/j.cell.2012.02.040.

Neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease

Biradar SM, Joshi H, Chheda TK.

Eur J Pharmacol. 2012 May 15;683(1-3):140-7. doi: 10.1016/j.ejphar.2012.02.042. Epub 2012 Mar 8.

Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease

Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, Drzezga A.

PLoS One. 2012;7(3):e31310. doi: 10.1371/journal.pone.0031310. Epub 2012 Mar 9.

Terpenoids as potential anti-Alzheimer's disease therapeutics

Yoo KY, Park SY.

Molecules. 2012 Mar 19;17(3):3524-38. doi: 10.3390/molecules17033524.

Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease

Strosznajder JB, Czapski GA, Adamczyk A, Strosznajder RP.

Mol Neurobiol. 2012 Aug;46(1):78-84. doi: 10.1007/s12035-012-8258-9. Epub 2012 Mar 20.

Potential roles of peroxisomes in Alzheimer's disease and in dementia of the Alzheimer's type

Lizard G, Rouaud O, Demarquoy J, Cherkaoui-Malki M, Iuliano L.

J Alzheimers Dis. 2012;29(2):241-54. doi: 10.3233/JAD-2011-111163.

Meta-analysis of the cystatin C(CST3) gene G73A polymorphism and susceptibility to Alzheimer's disease

Hua Y, Zhao H, Lu X, Kong Y, Jin H.

Int J Neurosci. 2012 Aug;122(8):431-8. doi: 10.3109/00207454.2012.672502. Epub 2012 Apr 20.

Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease

Brewer GJ.

Biofactors. 2012 Mar-Apr;38(2):107-13. doi: 10.1002/biof.1005. Epub 2012 Mar 22.

Neuroendocrinology-based therapy for Alzheimer's disease

Palm R, Ayala-Fontanez N, Garcia Y, Lee HG, Smith MA, Casadesus G.

Biofactors. 2012 Mar-Apr;38(2):123-32. doi: 10.1002/biof.1011. Epub 2012 Mar 22.

New and emerging treatments for Alzheimer's disease

Corbett A, Ballard C.

Expert Opin Emerg Drugs. 2012 Jun;17(2):147-56. doi: 10.1517/14728214.2012.675327. Epub 2012 Mar 23.

Increasing the success rate for Alzheimer's disease drug discovery and development

Becker RE, Greig NH.

Expert Opin Drug Discov. 2012 Apr;7(4):367-70. doi: 10.1517/17460441.2012.672409. Epub 2012 Mar 23.

Validation of apathy evaluation scale and assessment of severity of apathy in Alzheimer's disease

Hsieh CJ, Chu H, Cheng JJ, Shen WW, Lin CC.

Psychiatry Clin Neurosci. 2012 Apr;66(3):227-34. doi: 10.1111/j.1440-1819.2011.02315.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias